Fenofibrate Dosing for Hypertriglyceridemia
For adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dL), start fenofibrate at 54-160 mg once daily with meals, titrating based on response every 4-8 weeks, with a maximum dose of 160 mg daily. 1
Dosing Algorithm by Clinical Scenario
Severe Hypertriglyceridemia (≥500 mg/dL)
- Initial dose: 54-160 mg once daily with meals
- Titration: Adjust every 4-8 weeks based on lipid response
- Maximum dose: 160 mg once daily 1
- Primary goal: Prevent acute pancreatitis 2
Moderate Hypertriglyceridemia (175-499 mg/dL)
- Initial dose: 160 mg once daily with meals 1
- Goal: Reduce ASCVD risk through triglyceride lowering
- Consider: Statin therapy first if ASCVD risk ≥7.5% 2
Mixed Dyslipidemia
- Initial dose: 160 mg once daily with meals 1
- Target: Non-HDL-C <130 mg/dL when triglycerides 200-499 mg/dL 3, 4
Critical Renal Dose Adjustments
Renal function assessment is mandatory before initiating fenofibrate 5:
- eGFR ≥60 mL/min/1.73m²: Standard dosing (54-160 mg daily)
- eGFR 30-59 mL/min/1.73m²: Start at 54 mg daily; do NOT exceed 54 mg daily 5
- eGFR <30 mL/min/1.73m²: Contraindicated - do not use 5, 1
Monitor renal function:
- Baseline creatinine and eGFR
- Repeat within 3 months of initiation
- Every 6 months thereafter 5
- Discontinue if eGFR persistently drops to <30 mL/min/1.73m² 5
Administration Requirements
Fenofibrate MUST be taken with meals to optimize bioavailability 1. This is not optional—absorption is significantly reduced when taken on an empty stomach.
Monitoring Schedule
Lipid Monitoring
- Baseline: Fasting lipid panel before initiation
- Follow-up: Repeat at 4-8 weeks after starting or dose adjustment 1
- Ongoing: Every 3-12 months once stable 5
Response Assessment
- Discontinue therapy if inadequate response after 2 months at maximum tolerated dose (160 mg daily) 1
- Consider dose reduction if lipids fall significantly below target range 1
Combination Therapy Considerations
With Statins
- Gemfibrozil + statin: Contraindicated due to severe myopathy risk 5
- Fenofibrate + statin: May be considered (Class IIb) only when:
Safety with Combination Therapy
The combination of high-dose statin plus fenofibrate increases myopathy risk. Keep statin doses relatively low when combining 3, 4. Monitor creatine kinase if muscle symptoms develop.
Special Populations
Elderly Patients
- Dose selection based on renal function 1
- No dose adjustment needed if renal function normal 1
- Higher risk of renal impairment—assess eGFR carefully
Diabetic Patients
Fenofibrate can be used safely in diabetes and may improve glycemic control 6, 7. This contrasts with niacin, which worsens glucose metabolism 7.
Common Pitfalls to Avoid
Failing to assess renal function before initiation—this is the most critical safety issue with fenofibrate 5
Taking fenofibrate without food—significantly reduces drug absorption 1
Combining with gemfibrozil and statin—absolute contraindication due to severe myopathy risk 5
Using in severe renal impairment (eGFR <30)—contraindicated due to drug accumulation 5, 1
Ignoring persistent eGFR decline—must discontinue if eGFR drops to <30 persistently 5
Contraindications
Fenofibrate is absolutely contraindicated in 1:
- Severe renal impairment (eGFR <30 mL/min/1.73m²)
- Active liver disease
- Preexisting gallbladder disease
- Nursing mothers
- Known hypersensitivity to fenofibrate or fenofibric acid
Clinical Context
While fenofibrate effectively lowers triglycerides by 40-50% 8, 9, the 2013 ACC/AHA guidelines note that fenofibrate at 160 mg equivalent dosing did not reduce coronary heart disease morbidity and mortality in the ACCORD trial of diabetic patients 1. Therefore, the primary indication for severe hypertriglyceridemia is pancreatitis prevention, not cardiovascular risk reduction 2, 10.
For moderate hypertriglyceridemia with elevated ASCVD risk, statin therapy should be initiated or intensified first 2. Fenofibrate is considered only after addressing lifestyle factors, secondary causes, and optimizing statin therapy 2.